<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26559">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662115</url>
  </required_header>
  <id_info>
    <org_study_id>CRS-2012-05</org_study_id>
    <nct_id>NCT01662115</nct_id>
  </id_info>
  <brief_title>Nicotine Gum Recovery After Colorectal Surgery</brief_title>
  <official_title>Does Nicotine Gum Enhance Bowel Recovery After Colorectal Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleveland Clinic Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleveland Clinic Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the use of nicotine gum in the
      postoperative period influences surgical outcome in patients undergoing colorectal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main hypothesis of this study is that use of nicotine gum after colorectal surgery will
      accelerate recovery of bowel function.  Eligible patients include all patients undergoing
      segmental small bowel or large bowel resection with a planned primary anastomosis, planned
      removal of the nasogastric tube at the end of the surgery, and administration of clear
      liquids on post-operative day one.  Patients who have an ileostomy or colostomy created will
      be excluded.  Patients enrolled in the study will be randomized to one of three groups:
      nicotine gum, regular gum, or no gum.  Patients randomized to nicotine gum or regular gum
      will chew the gum three times a day for 1 week.  The main outcome measure is time to first
      bowel movement or flatus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bowel function recovery</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first bowel movement or flatus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of postoperative hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative vomiting</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Episodes of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of NG Tubes</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nasogastric tube (re)insertions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Post-operative Ileus</condition>
  <arm_group>
    <arm_group_label>Nicotine gum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 subjects who will actually get the intervention medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regular chewing gum</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>100 subjects who will be part of a  control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No gum</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>100 subjects who will not get neither the intervention nor the placebo gum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <description>Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first</description>
    <arm_group_label>Nicotine gum</arm_group_label>
    <other_name>Nicorrete gum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regular chewing gum</intervention_name>
    <description>Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first</description>
    <arm_group_label>regular chewing gum</arm_group_label>
    <other_name>Sugarlees chewing gum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to freely give written informed consent to participate in the study and have
             signed the Informed Consent Form;

          -  Due to undergo small and/or large partial bowel resection via laparotomy or
             laparoscopy;

        Exclusion Criteria:

          -  Prior intestinal surgery

          -  Mentally incompetent or unable or unwilling to provide informed consent or comply
             with study procedures

          -  American Society of Anesthesiologists (ASA) Class IV or V;

          -  History of abdominal carcinomatosis;

          -  History of radiation enteritis;

          -  Children &lt; 18 or adults &gt; 85 years of age

          -  Pregnant women

          -  Current cigarette, cigar smokers and chewers of tobacco.  ex smokers who quit less
             than 3 months ago.

          -  Patients requiring postoperative ventilation, pressor requirement or ICU stay

          -  Patients with prior cardiovascular disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ERIC G WEISS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KARLA ARANCIBIA, MD</last_name>
    <phone>954--659-5241</phone>
    <email>ARANCIK@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorge Canedo, MD</last_name>
    <phone>954-659-5861</phone>
    <email>canedoj@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KARLA ARABACIAN, MD</last_name>
      <phone>954-659-5241</phone>
      <email>ARABACK@CCF.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Jorge CANEDO, MD</last_name>
      <phone>954-659-5861</phone>
      <email>CANEDOJ@CCF.ORG</email>
    </contact_backup>
    <investigator>
      <last_name>ERIC G WEISS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 9, 2012</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Clinic Florida</investigator_affiliation>
    <investigator_full_name>Eric Weiss</investigator_full_name>
    <investigator_title>DIO and Chairman of Graduate Medical Education at Cleveland Clinic Florida,</investigator_title>
  </responsible_party>
  <keyword>ILEUS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ileus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
